Did Pediatrix Medical beat or miss consensus estimates last quarter?

What factors drove the changes in Pediatrix Medical's revenue and profit?

What is the market's earnings forecast for Pediatrix Medical next quarter?

What is Pediatrix Medical's latest dividend and current dividend yield?

What guidance did Pediatrix Medical's management provide for the next earnings period?

What were the key takeaways from Pediatrix Medical's earnings call?

What does Pediatrix Medical do and what are its main business segments?

What were the key takeaways from Pediatrix Medical’s earnings call?

- **Record EBITDA Growth**: $87 million Q3 adjusted EBITDA, up 12% year-over-year, with 1.7 million shares repurchased.
- **Technology Differentiation**: BabySteps system reduces NICU documentation by 30%, driving clinical efficiency and outcomes.
- **Financial Strength**: 1x net leverage and $340 million cash provide flexibility for growth.
- **Strategic Focus**: Neonatology leadership with 1,300+ physicians and 37 million patient-day data warehouse.


**【CEO Remarks】**
- **Strong Q3 Results**: Adjusted EBITDA of $87 million exceeded expectations, driven by portfolio restructuring and expense control. Full-year outlook for adjusted EBITDA is $270–$290 million, reflecting cautious optimism.
- **Share Buybacks**: 1.7 million shares repurchased year-to-date, signaling confidence in long-term value.
- **Strategic Focus**: Emphasized neonatology leadership with 1,300+ physicians and BabySteps technology, a proprietary system improving NICU outcomes through clinical decision support and reduced documentation burden.
- **Research and Innovation**: 1,395 peer-reviewed publications and 72 clinical studies, positioning as a leader in neonatal research and quality care.

**【CFO Financial Commentary】**
- **Revenue Performance**: Consolidated revenue decline due to restructuring, but same-unit growth of 8% (pricing +7.5%, volumes +0.4%). Key drivers: RCM collections, acuity, administrative fees, and favorable payer mix.
- **Cost Management**: Operating cash flow of $138 million (vs. $96 million prior year), ending with $340 million cash and net debt of $260 million (1x leverage ratio).
- **Non-Operating Income**: $21 million gain from divested businesses, offsetting modest G&A increases.

**【Q&A Highlights】**
- **Capital Allocation**: Cautious on debt but open to strategic acquisitions; share buybacks continue as a priority.
- **Pricing Durability**: Collections (33%), acuity (20%), and administrative fees (10%) drove Q3 pricing; expect variability in 2026.
- **Market Dynamics**: Strong demand for neonatal support from hospitals; BabySteps technology differentiates Pediatrix in competitive landscape.
- **Subsidy Impact**: Hopeful about exchange plan subsidies but no direct impact on business observed.


Pediatrix Medical Group, Inc. (MD) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

MD

MD fundamentals

You can ask Aime